Skip to main content
Download PDF

Tetraspanin CD82 is necessary for muscle stem cell activation and supports dystrophic muscle function

Skeletal Muscle volume 10, Article number: 34 (2020) Cite this article

Abstract

Background

Tetraspanins are a family of proteins known to assemble protein complexes at the cell membrane. They are thought to play diverse cellular functions in tissues by modifying protein-binding partners, thus bringing complexity and diversity in their regulatory networks. Previously, we identified the tetraspanin KAI/CD82 as a prospective marker for human muscle stem cells. CD82 expression appeared decreased in human Duchenne muscular dystrophy (DMD) muscle, suggesting a functional link to muscular dystrophy, yet whether this decrease is a consequence of dystrophic pathology or a compensatory mechanism in an attempt to rescue muscle from degeneration is currently unknown.

Methods

We studied the consequences of loss of CD82 expression in normal and dystrophic skeletal muscle and examined the dysregulation of downstream functions in mice aged up to 1 year.

Results

Expression of CD82 is important to sustain satellite cell activation, as in its absence there is decreased cell proliferation and less efficient repair of injured muscle. Loss of CD82 in dystrophic muscle leads to a worsened phenotype compared to control dystrophic mice, with decreased pulmonary function, myofiber size, and muscle strength. Mechanistically, decreased myofiber size in CD82−/− dystrophic mice is not due to altered PTEN/AKT signaling, although increased phosphorylation of mTOR at Ser2448 was observed.

Conclusion

Basal CD82 expression is important to dystrophic muscle, as its loss leads to significantly weakened myofibers and impaired muscle function, accompanied by decreased satellite cell activity that is unable to protect and repair myofiber damage.

Background

The tetraspanins are a class of transmembrane proteins known to regulate the assembly of protein complexes at the cell membrane [1,2,3,4]. The tetraspanin-associated proteins are very diverse and change greatly depending on cell type, cellular state, and tissue conditions, such as normal or cancer cells [5]. Thus, the tetraspanin web represents a very dynamic class of proteins that play a role in a number of regulatory networks. Importantly, tetraspanins have been shown to signal through other protein families, such as integrins, making this an extremely broad network with tremendously varied functional translational mechanisms. One tetraspanin, CD82, was first discovered as a potential anti-metastatic marker for prostate cancer [6,7,8]. It is known to have pro-adhesive properties, and its expression in cancer cells is often linked to good prognostic outcome. CD82 was named as C33, 4F9, IA4, and R2 [9,10,11] prior to its classification within the clusters of differentiation nomenclature [12]. CD82 has a typical tetraspanin structure, with intracellular N- and C-termini and two extracellular loops, a small (EC1) and a large (EC2) loop [11]. Glycosylation sites are present on the EC2, accounting for additional protein variability, while the transmembrane helix 3 (TM3) and 4 (TM4) domains contain polar residues thought to mediate intramolecular interactions [13]. CD82 has also been shown to interact with various integrin complexes, resulting in the mediation of cellular adhesion to the extracellular matrix by fibronectin and laminin binding [14,15,16]. While CD82 expression is fairly ubiquitous, there is variation in the transcripts encoded with some isoforms lacking the C-terminus or transcript variants lacking specific exons [17]. While these transcriptional variants are known, their specific function has not been elucidated.

Our previous study reported expression of CD82 in both quiescent and activated human satellite cells, with cells positive for CD82 exhibiting strong myogenic activity both in vitro and in vivo. Recent single cell RNA seq studies have also confirmed robust CD82 expression in mouse satellite cells [18, 19]. In hematopoietic stem cells, CD82 expression is typically indicative of quiescence; thus, CD82 loss of function leads to over-proliferation of cells [20, 21]. In contrast, knock-down of CD82 in myogenic cells derived from induced pluripotent stem cells (iPSCs) reduces myoblast proliferation and impairs cell activation [14, 22]. In human myoblasts, CD82 was shown to associate with α7 integrin and α-sarcoglycan, suggesting it might have a role in linking α7β1 integrin with the sarcoglycan complex [14]. Furthermore, CD82 expression is also decreased in myogenic cell lines and tissue from DMD patients compared to normal controls, while it is increased in regenerating fibers [14]. Whether decreased expression of CD82 in DMD muscle is downstream of the degenerative progressive dystrophic pathology or is part of a compensatory mechanism meant to slow muscle degeneration is currently unclear.

In the present study, we determined the consequences of loss of CD82 function in both normal (CD82−/−) and dystrophic (CD82−/−:mdx5cv) mouse skeletal muscle. CD82−/− muscles show impaired regeneration following acute injury. While the number of Pax7+ satellite cells CD82−/− mice is not different from WT control, satellite cells from CD82−/− mice exhibit impaired and/or delayed activation and decreased proliferation. We also show that loss of CD82 expression in dystrophic muscle (CD82−/−:mdx5cv) leads to a worsened phenotype compared to control mdx5cv mice. Muscle strength and resistance to mechanical strain are significantly decreased, accompanied by myofiber size being significantly smaller in CD82−/−:mdx5cv mice. Mechanistically, smaller myofibers in CD82−/−:mdx5cv mice are not due to decreased pAKT signaling at neither Ser 473, nor Thr 308, nor to increased PTEN expression. In contrast, mTOR phosphorylation at Ser 2448 was increased in CD82−/−:mdx5cv compared to mdx5cv mice. In summary, basal CD82 expression is important to dystrophic muscle, as its loss leads to significantly weakened myofibers and impaired muscle function, accompanied by decreased muscle stem cell activity that is unable to protect and repair myofiber damage.

Methods

Animal husbandry

Six-week-old male and female wild-type C57BL/6 mice were ordered from the Jackson Laboratories (Bar Harbor, ME) and paired to establish an in-house colony. Mdx5cv dystrophic males and females were bred as previously described [23, 24]. Breeding pairs of previously reported CD82 knockout mice (CD82−/−) (C57BL/6 background) [25] were obtained from Dr. Cindy Miranti, following approval by the National Cancer Institute Animal Resource Program. CD82−/− mice were bred into mdx5cv mice (C57BL/6 J background) to generate CD82:dystrophin double-null mice (CD82−/−:mdx5cv). Because the dystrophin gene is on the X-chromosome, female mice homozygote for both CD82 and dystrophin allele mutations were generated, while males are homozygotes for the CD82 mutation and hemizygotes for the dystrophin mutation. Male and female mice were analyzed in these studies and cohorts were matched for both age and sex in all comparisons. For each experiment, cohorts of 6-10 mice were used to ensure sufficient statistical power. Mice were bred and euthanized by CO2 asphyxiation, followed by cervical dislocation. Mice of all genotypes were analyzed at 2 and 4 months of age, as well as when they reached the age of 1 year. All experiments involving vertebrate animals were approved and conducted in accordance with IACUC Institutional Regulations at Boston Children’s Hospital, Boston, MA.

Genotyping

Upon weaning at 21 days, CD82−/− mice were ear-notched using a punch biopsy tool and ear-tagged. DNA was extracted using the KAPA HotStart Mouse Genotyping Kit (Item no. 07961804001, KAPA Biosystems) and CD82−/− genotyping analysis was performed using the KAPA Genotyping kit according the manufacturer’s recommendations. Primers used for genotyping included a common 5′ sequence targeting both the WT and CD82−/− alleles (5′-AGT GGG CCC TGG CTT TCA AC-3′), while allele-specific reverse primer sequences were provided by Dr. C.K. Miranti (antisense WT 5′-GTC ACA GAA CCT GCT GGG AGA G-3′; antisense CD82−/− recognizing the PGKneo targeting cassette 5′-CTA AAG CGC ATG CTC CAG AC-3′). Primers were used at a final concentration of 10 mM and DNA was amplified in a thermocycler under the following conditions: 95 °C for 3 min; 95 °C for 15 s, 60 °C for 15 s, 72 °C for 15 s for 35 cycles, followed by a final extension at 72 °C for 5 min. The WT and CD82−/− primers were run in separate reactions to prevent one band being favored in the amplification. PCR products were then run on a 2% agarose gel and imaged using a Gene Flash biomager (Syngene). The WT band was expected at 300 bp and the CD82−/− band at 180 bp.

Mdx5cv genotyping was also conducted using the KAPA genotyping kit, with genotyping results confirmed by a Sanger sequencing protocol previously established [26, 27]. Primers used for initial genotyping included forward primer (5′-ATT TGG AAG CTC CCA GAG AC-3′) and reverse primer (5′-TGC TTT AGC TTC AGA AGT CA-3′). DNA was amplified in a thermocycler under the conditions recommended by the manufacturer: 95 °C for 3 min; 95 °C for 15 s, 60 °C for 15 s, 72 °C for 15 s for 35 cycles followed by a final extension step at 72 °C for 5 min. Amplified products were run on a 2% agarose gel and imaged with the Gene Flash bioimager, with the band expected at 250. After confirmation of a visible band, the PCR product was sent to the Boston Children’s Hospital Sequencing Core to obtain the Sanger sequencing which was used to determine the genotype.

Serum creatine kinase measurements

Serum creatine kinase levels were measured using the Liquid Creatine Kinase Reagent Set from Pointe Scientific [28]. Mice were restrained and 100–150 μL of blood was collected via a survival tail vein nick into BD Microtainer serum separator tubes from age-matched C57BL/6, CD82−/−; mdx5cv and CD82−/−:mdx5cv mice. Blood was allowed to coagulate for 30 min at room temperature and then centrifuged and 5 μL of serum was used in the assay as instructed by the manufacturer. For each blood sample, three measurements were taken and averaged. Values are reported as means and standard errors of the mean.

In situ evaluation of muscle function

Mice were anesthetized with sodium pentobarbital (80–100 mg/kg body mass) with supplemental doses administered as necessary. The animal was placed on a temperature-controlled (38 °C) test stand (Aurora Scientific model 809B, Aurora, Ontario, Canada) where the knee was stabilized to a horizontal support and the severed tendon of the tibialis anterior (TA) attached to the lever arm of a dual mode muscle lever system (Aurora Scientific model 305C-LR). TA contractions were induced by supramaximal 200 μs square-wave pulses (Aurora Scientific, model 701A muscle stimulator) delivered to platinum electrodes inserted behind the knee near the peroneal nerve. All contractions were initiated at the optimal length (Lo) for tetanic force and were separated by 60 s intervals to minimize fatigue. Muscles were stimulated with brief trains (150 ms) at frequencies from 20–300 Hz in order to establish the relationship between force and stimulation frequency. During eccentric contractions, the muscle was stimulated for 233 ms at the frequency giving maximum force (200–300 Hz). During the first 100 ms of stimulation, the muscle was held at Lo and during the subsequent 133 ms the muscle was lengthened 20% of fiber length at a velocity of 1.5 fiber lengths/s. The muscle was returned to Lo 400 ms after the conclusion of the stretch. The eccentric contraction protocol consisted of a series of 5 eccentric contractions that was bracketed by an initial and a final protocol contraction conducted with the muscle maintained at Lo. The peak force attained during the first 100 ms of the initial, eccentric, and final contractions was used to calculate relative force (force/force on the initial protocol contraction). Specific force was calculated as active tetanic force divided by TA physiological cross-sectional area (pCSA). The pCSA of the TA was calculated as muscle mass divided by the product of FL and muscle density, with fiber length and muscle density taken as 0.60 Lo and 1.06 mg/mm3, respectively.

Plethysmography

Plethysmography was performed in the IDDRC Neurobehavioral Core Facility at Boston Children’s Hospital using a whole body SCIREQ TECHNOTE 070 plethysmograph (SCIREQ Respiratory Equipment Inc., Montreal, Canada). The assay studies the ventilatory parameters in conscious, spontaneously breathing subjects by monitoring changes in pressure and flow. Mice were placed in the plethysmograph and allowed to acclimate for 15 min. Measurements, including inspiratory time and tidal volume, were taken on 5 mice/genotype every 15 s for the next 30 min and compared using a t test and Prism Graphpad 8.

Cardiotoxin injury of mice and immunofluorescence staining of Pax7+ cells

Anesthetized C57BL/6 and CD82−/− female mice were injected in the belly of the right tibialis anterior (TA) with 15 μg of cardiotoxin (15 μl volume) per approved institutional protocols, and the left TA was used as a contralateral control, in addition to the quadriceps muscles. Nine mice for each genotype and per each time point were injected with cardiotoxin, collected at 7 or 21 days post injury and frozen in cold isopentane for histological analyses and for determining the number of Pax7+ cells in the tissue. Ten micron frozen sections of tibialis anterior (TA) or quadriceps muscle tissue were taken from the approximate belly of the muscle. For cardiotoxin-injured muscle, sequential sections were taken to locate the injured area. Tissue sections were stained with hematoxylin and eosin as previously described [28]. The size of the injury area was determined by immunofluorescence staining using anti-laminin (Sigma L9393 1:1000) and anti-embryonic myosin heavy chain (clone F1.652 from DSHB, 1:50). The entire tissue sections were imaged and images were stitched together using the Photomerge function in Photoshop (Adobe). Fiber dimensions (minimum Feret’s diameter and myofiber area) were measured using NIH ImageJ.

For detection of satellite cells in tissue sections via Pax7 immunofluorescence analyses, sections were cut at 8 μm and fixed in 4% PFA for 20 min. Sections were washed with TBST (1x TBS with 0.3% Tween 20) 3 x 5 min, followed by blocking with 2.5% normal goat serum for 30 min. Primary antibodies used were Pax7 (Developmental Studies Hybridoma Bank, 334 μg/ml dil 1:20) together with dystrophin (Abcam, ab15277) dil 1:100 or laminin (Sigma L9393) 1:1,000 diluted with TBST and incubated at 4 °C overnight. Slides were washed with TBST 3 x 10 min before adding the appropriate secondary antibodies diluted 1:500 in TBST for 1 h at room temperature. Slides were again washed in TBST 3 x 10 min and mounted in Vectashield/DAPI. Slides were scanned on an Olympus VS120 microscope. Regions of interest were selected from the slide scan and the number of Pax7-positive nuclei and number of fibers (as defined by their outline with dystrophin staining) were manually counted. Per each animal (n = 9/group), between 900 and 1300 myofibers were analyzed and the number of Pax7+ cells was counted and normalized to the number of regenerating myofibers; comparisons were made using an unpaired Student’s t test.

Primary cell isolations: satellite cells

Satellite cells were isolated using the MACS mouse Satellite Cell Isolation Kit (Item no. 130-104-268, Miltenyi Biotec), followed by positive selection for integrin alpha7-positive cells (Miltenyi item no 130-104-261). Skeletal muscles from C57BL/6 (WT), CD82−/−; mdx5cv and CD82−/−:mdx5cv mice were dissected, minced, and dissociated with 5 mg/mL collagenase D and 1.2 U/mL dispase II for approximately 45 min at 37 °C. After complete dissociation, tissue slurry was filtered through a 100-μm filter and centrifuged. Red blood cell lysis was performed using Red Lysis Buffer (Qiagen Item no. 158904, Valencia, CA, USA), filtered through a 40-μm filter and centrifuged again. Myogenic cells were isolated using MACS enrichment columns starting with the Satellite Cell isolation kit (depletion of endothelial and fibroadipogenic progenitors) followed by positive selection for integrin-α7 expressing cells (satellite cells). Satellite cell populations were plated in triplicates on 4 and 8 well Permanox slide chambers coated with recombinant laminin 511(Biogems RL511S) in growth medium (Ham’s F-10 supplemented with 20%FBS, 1× penicillin/streptomycin/glutamine (PSG) and 10 ng/mL bFGF. Slide chambers were fixed in 4%PFA for 20 min at RT at 24, 48, and 72 h and analyzed by immunofluorescence for expression of the myogenic transcription factors Pax7 (DSHB concentrated supernatant, dil 1:200) and MyoD (Santa Cruz m-318, dil 1:100 and MyoD G-1 sc377460), the cell activation marker Ki67 (Cell Signaling 9129S, dil 1;400) and the senescence/pre-apoptosis marker H2A.X (Ser139), also called H2Aγ (Cell Signaling Technology 2577S dil 1:400). Following fixation, cells were briefly rinsed in PBS and permeabilized for 3 min at RT in PBS/0.5% Triton-X. Cells were again washed 2× in 1XPBS and blocked in PBS/10% fetal bovine serum 0.1%Triton X for 45 min (blocking solution). Primary antibodies were diluted in blocking solution and incubated overnight at 4 °C. Slides were washed 3 x 10 min in 1XPBS and incubated with secondary antibodies for 1 h at room temperature. Slides were again washed in 1XPBS as above and mounted using DAPI/Vectashield (VectorLabs). At each timepoint, the percentages of Pax7+MyoD−; Pax7+MyoD+; Pax7+Ki67+; MyoD+ H2Aγ+ cells were counted. A minimum of 100 total cells was counted per each well and timepoint, with 6–10 independent isolations analyzed/genotype. Comparisons of the percentage of cells between genotypes were made using an unpaired Student’s t test and GraphPad8 software.

For cell cycle analyses, cells were trypsinized and fixed in ice cold 70% ethanol for 2 h, then stored at − 20 °C until prior to FACS analysis as we previously described [29]. Briefly, cells were spun, washed in 1X PBS, and then incubated for 30 min at RT with a solution of propidium iodide (20 μg/mL) in 1xPBS supplemented with 0.1%Triton X and 0.2 mg/mL DNase-free RNase A. Cells were then washed again in 1XPBS before being analyzed by FACS as previously described [29].

For fusion assays, 50,000 cells/sample were plated in 4-well slide chambers and grown to confluence. Cells were differentiated in DMEM (1 g/L glucose) 2% FBS and 1X ITS (insulin transferrin selenium supplement (ITS-Gibco thermo Scientific 51500-056) for up to 5 days. Cells were fixed in 4%PFA, permeabilized, and blocked as described above. Cells were incubated overnight 4 °C with anti-myosin heavy chain antibody (clone MF-20, DHSB) diluted 1:50. The fusion index was calculated as the percentage of nuclei fused into MHC-positive myotubes/total number of nuclei. Fusion indices were compared between genotypes using a t test and GraphPad8 software.

Isolation of single myofibers

Single myofibers were isolated as previously described [30]. Briefly, extensor digitorum longus muscle was isolated from WT and CD82−/− mice and digested in collagenase D as described [30]. Muscle tissue was mildly digested with Collagenase-DMEM to release single muscle fibers, which were then transferred to 6-well plates and fixed in 4% PFA, pH 7.4, at room temperature (T0). Fibers to be cultured were placed for 48 h in growth medium prior to being fixed in PFA, immunostained and imaged on a Nikon microscope. Comparisons of the percentage of cells between genotypes were made using a t test and GraphPad8 software.

Histological analyses

Muscle tissue was flash frozen in liquid nitrogen-chilled isopentane as described [31]. Sections of 8 μm were taken using a cryostat (Leica Biosystems, Wetzlar, Germany) and subjected to hematoxylin and eosin (H&E). Sections were fixed for 5 min, placed in 70% ethanol followed by rehydration in water. Slides were stained in Harris modified hematoxylin solution (Sigma-Aldrich HHS32) for four and a half minutes, then washed in water before being submerged in eosin Y solution (Sigma-Aldrich HT110116) for a minute and a half, and then washed again in water until clear. The slides were dehydrated in an ascending alcohol series, cleared in xylene, and then mounted with cytoseal (Richard-Allan Scientific™ Cytoseal 60™ Thermo Scientific, 8310-16). All slides were imaged on a brightfield Nikon E800 microscope (Nikon, Tokyo, Japan) using SPOT software (Diagnostic Instruments, Sterling Heights, Michigan, USA). Images were acquired for entire sections and photomerged using Adobe Photoshop. Depending on the depth of the section analyzed, between 505 and 840 myofibers were analyzed per animal (n = 6/cohort). Fiber measurements (minimum Feret’s diameter, H&E stains) were analyzed using ImageJ (NIH, Bethesda, Maryland, USA). Statistical analyses were performed using GraphPad Prism 8 (GraphPad Software, San Diego, CA, USA).

Sirius Red staining

Slides were dehydrated in a descending alcohol series, before being washed in tap water and placed in hematoxylin. Slides were then washed in tap water, Scott’s Blue Water, and then water again before being stained in a 0.1% Sirius Red solution (Rowley Biochemical SO-674). After staining, slides were washed in acidified water and then dehydrated in an ascending alcohol series before being cleared in xylene and mounted with Cytoseal. Images were acquired for entire sections and photomerged using Adobe Photoshop. Merged images were opened in ImageJ and areas with poor staining were cropped out of the image and turned the background color white (<10% of the entire section). The new image was converted to an 8-bit image and thresholded to turn the entire tissue section black. This section was measured as the total tissue area. Images were then thresholded to turn the Sirius Red staining black and the remaining tissue section white. The black area was measured and divided by the total tissue area calculated above to give a percentage of fibrosis in the tissue section. Percentages were compared between genotypes using a t test and Graphpad 8.

Western blotting

Skeletal muscle tissue was snap frozen and ground to a fine powder using a mortar and pestle precooled in liquid nitrogen. The tissue powder was resuspended in RIPA buffer with Protease and Phosphatase Inhibitor Cocktail Set III, EDTA Free (Item nos. 539134-1SET and 524627-1ML, Millipore Sigma). Lysates were sonicated for 3 × 5 s and spun at 13,000 RPM to pellet tissue debris, while the supernatant was collected. Protein concentration was determined using PierceTM BCA protein assay kit (Thermo Scientific). Samples were made with 4X NUPAGE loading buffer and .05% BME, boiled at 90 °C for 10 min and spun again at 13,000 RPM; the supernatant was loaded onto a 4–12% Nupage Bis-Tris Gel (Item no, NP0322, Invitrogen) or a 4–20% Tris-Glycine gel (Item no. XP04200, Invitrogen), depending on the target protein to be detected. Protein samples were run at 80 V for 10 min followed by 115 V on ice for 1.5 h before being transferred to a nitrocellulose or PVDF membrane using a wet transfer. Membranes were blocked for 1 h at room temperature in 5% non-fat dry milk in TBS-0.1% Tween (TBST) or Odyssey blocking buffer in PBS (LI-COR #927-40000). Primary antibodies (listed in Supplementary Table 1) were diluted as specified and incubated overnight at 4 °C. Membranes were washed three times, 10 min each, with TBST at room temperature, hybridized with an HRP-Conjugated or IRDye 800 (LI-COR #611-132-122) secondary antibody for 1 h at room temperature, and washed with TBST three times for 10 min each. Detection of proteins probed with HRP-conjugated secondary was determined using Western Lightning ® Plus-ECL Enhanced Chemiluminescence Substrate (Item no. NEL103001EA, Perkin Elmer) and blots were exposed on ProSignalTM Blotting Film (Item no. 30-507L, Prometheus Protein Biology Products, Genesee Scientific) and detection of proteins probed with IRDye 800 was done using the Licor Odyssey 9120 Infrared Imaging System. To ensure equal loading of protein, HRP-conjugated blots were stripped using RestoreTM Western Blot Stripping Buffer (Item no. 21059, Thermo Scientific) and hybridized with anti-desmin (Item no. ab8592, Abcam); IRDye 800 hybridized blots were normalized with anti-GAPDH polyclonal antibody (Invitrogen #TAB1001). Optical density was measured by FIJI (Image J) Software.

Results

Our previous study identified CD82 as an effective marker to prospectively isolate human muscle stem cells and found its expression variably decreased in cell lines and muscle tissues from patients with Duchenne muscular dystrophy [14]. To address the functional role of CD82 in normal and dystrophic muscle, we took advantage of a previously generated CD82 knock-out (CD82−/−) mouse strain, which did not show any gross abnormality [25]. The genotype of CD82−/− mice was first confirmed by PCR and RT/PCR (Supplementary Figure 1A) followed by sequence analysis on RNA extracted from WT and CD82−/− skeletal muscle. This confirmed the presence of an 83 bp deletion that encompassed exon 2, which includes the ATG start site, as previously reported [25]. Western blot analyses using an antibody previously reported to recognize mouse CD82 (m-35) [9], confirmed the absence of glycosylated and non-glycosylated CD82 proteins (Supplementary Figure 1B). A small 10 kDa band was seen in both WT and CD82−/− tissues, suggesting the presence of an alternative product or a small cross-reactive protein. Immunofluorescence studies detected expression of CD82 at the membrane and in cytoplasm of primary mouse myoblasts (Supplementary Figure 1C) and in the cytoplasm of myotubes (Supplementary Figure 1D) of WT animals, including intracellular vesicles. Western blot analyses of differentiating mouse C2C12 lysates detected an increase in expression of CD82 in myotubes up to 10 days following differentiation (Supplementary Figure 1E). Thus, CD82 expression is detected in both mononuclear myogenic cells and in myotubes, although with different subcellular localization.

To study the function of CD82 under basal (non-dystrophic) conditions, in situ evaluation of muscle force, serum creatine kinase levels, muscle mass, and histological assessment analyses were performed on CD82−/− mice compared to age-matched WT controls. H&E stain under basal conditions did not show any gross histological abnormality between WT and CD82−/− skeletal muscle (Fig. 1a, b). Average myofiber sizes measured via minimum Feret’s diameter and compared via t test showed a significant decrease in CD82−/− compared to WT myofibers both at 2-month-old (Fig. 1c) and 1-year-old mouse cohorts (Fig. 1g). Frequency distribution plots at 2 months and 1 year of age did not show significant differences between the genotypes (Fig. 1d, h). The weight of the TA muscle did not appear to significantly differ between WT and CD82−/− animals (Fig. 1i), nor assessments of peak force normalized to the cross sectional area of muscles (Fig. 1j), force generated following serial eccentric contractions (Fig. 1k), or serum CK values (Fig. 1l), which appeared normal in CD82−/− mice compared to WT controls, while mdx5cv sera were used as a positive control for the CK assay (Fig. 1l). Histological analyses were also performed under regenerating conditions (Fig. 2), where 9 WT and 9 CD82−/− TA muscles were injured with cardiotoxin and allowed to undergo repair for 7 or 21 days. Following injury, CD82−/− muscle presented with significantly delayed regeneration and reduced myofiber size at both 7 days following injury (Fig. 2a, b, quantifications in c, d) and at 21 days (Fig. 2e, f, quantifications in g, h). The overall size of muscle injury was assessed by staining for laminin and embryonic myosin in non-injured CD82−/− muscle (negative control, Fig. 2i), injured WT (Fig. 2j), and injured CD82−/− (Fig. 2k) muscles (quantification in 2L). To address whether the delayed regenerative capacity of CD82−/− muscle was due to a decreased number of satellite cells, the number of Pax7-expressing cells was analyzed in control and CD82−/− muscle tissue sections using both uninjured and regenerating muscle. Per each animal (n = 9/group), between 900 and 1300 myofibers stained for dystrophin were analyzed for presence of adjacent Pax7+ satellite cells. No significant difference was found in the total number of Pax7+ cells under basal or regenerating conditions (Supplementary Figure 2). To further confirm this data, myofiber explants of EDL muscles were obtained from WT and CD82−/− mice and single myofibers were immunostained for Pax7, which confirmed the number of Pax7+ cells did not differ between the genotypes (Supplementary Figure 2, bottom panels). These results concluded that the impairment in muscle regeneration observed in injured CD82−/− muscles is not due to a decrease in Pax7+ satellite cell number.

Fig. 1
figure 1

CD82KO skeletal muscle shows no gross histological or functional abnormalities but has smaller myofibers. a, b H&E representative images of 8-week-old WT and CD82−/− tibialis anterior (TA) muscles show predominantly normal tissue in both strains. c Analyses of myofiber size via minimum Feret’s diameter measurements show significant difference in myofiber size between the two strains. Between 505 and 840 myofibers were measured per each animal, n = 6 animals/genotype. d Myofiber distribution plots of WT and CD82−/− at 8 weeks. e, f H&E representative images of 1-year-old WT and CD82−/− TA muscles, respectively. g Analyses of myofiber size via minimum Feret’s diameter measurements show significant difference between the two strains. h Myofiber distribution plots of WT and CD82−/− at 1 year. i Comparison of TA weight does not show significant differences between genotypes. j Peak force measurements normalized to CSA and k relative force measurements following serial tetanic stimulations do not show significant differences between genotypes. l Serum creatine kinase levels are normal and undistinguishable between WT and CD82−/− mice. Sera from mdx5cv mice were used as positive controls. Each dot represents an independent animal. ***p < 0.001; ****p < 0.0001. N = 6–10 animals/genotype in each experiment, with the exception of CK analyses (l), where a minimum of 20 mice were analyzed per genotype

Full size image
Fig. 2
figure 2

CD82KO skeletal muscle shows delayed regeneration with smaller myofibers. a, b H&E representative images of regenerating WT and CD82−/− muscles at 7 days. Comparisons of myofiber size at 7 days following CTX injury via minimum Feret’s diameter measurements (c) and myofiber distribution plots (d) show significant differences between the two strains using t tests. e, f H&E representative images of regenerating WT and CD82−/− muscles at 21 days. Minimum Feret’s diameter comparisons (g) and myofiber distribution plots (h) at 21 days following CTX injury show significant differences between the two strains using t tests (i–k) Immunofluorescence images of entire sections stained for laminin (red) and embryonic MHC, which labels regenerating fibers (green). i is a control immunostaining of non-injured CD82−/− muscle (no e-MHC+ fibers), whereas j and k are WT and CD82−/− injured muscles 7 days following injury, respectively. l Graph of percentages of regenerating fibers in non-injured and cardiotoxin injured muscles. ***p < 0.001; ****p < 0.0001

Full size image

To determine if CD82−/− satellite cells exhibited impairment in activation and/or cell division, primary myogenic cultures were established (Fig. 3). Satellite cells were extracted from pooled skeletal muscles of WT or CD82−/− animals using an established two-step magnetic column enrichment protocol, first via depletion of fibro-adipogenic and endothelial progenitors followed by positive selection of α7-integrin expressing cells (Miltenyi Biotec) [32]. Cells were plated in slide chambers and cultured in growth medium supplemented with bFGF to promote activation (n = 6-10 isolations/genotype). At 24, 48, and 72 h following isolation, cells were fixed and immunostained for Pax7 with MyoD and Pax7 with Ki67 to determine the percentage of quiescent and activated satellite cells, while co-staining of MyoD with H2Aγ was used to determine the percentage of myogenic cells undergoing premature senescence and in a pre-apoptotic state, defined by increased phosphorylation at Ser 139 of H2A.X [33] (Supplementary Figure 3A-D). Co-expression of MyoD and H2Aγ showed no significant difference in senescent/pre-apoptotic cell number between WT and CD82−/− cultures at all timepoints analyzed (Supplementary Figure 3A-C). Consistent with these findings, the number of non-adherent cells in the cultures did not differ between the two genotypes at each timepoint (Supplementary Figure 3D). Percentages of Pax7+MyoD- and Pax7+MyoD+ cells were calculated at 24, 48, and 72 h post isolation and compared between genotypes. Compared to WT cultures (Fig. 3a), CD82−/− cultures (Fig. 3b) contained significantly more Pax7+MyoD- cells at both 48 and 72 h following isolation (Fig. 3c) and significantly less Pax7+MyoD+ cells at 0 and 72 h (Fig. 3d). Notably, at 48 h, a significant increase in Pax+MyoD+ activated satellite cells was observed in CD82−/− cultures compared to WT, which was completely reversed at 72 h, when ~ 20% Pax+MyoD+ cells were observed in CD82−/− cultures, compared to ~ 80% in WT ones (Fig. 3d). Conversely, ~ 5% of quiescent Pax7+MyoD− were seen at 72 h in WT cultures, while the percentage of quiescent (inactive) Pax7+MyoD− cells sharply increased in CD82−/− cultures to > 60% (Fig. 3c). These findings indicated that loss of CD82 expression results in transient activation of the satellite cells that is not sustained. In addition, the percentage of Pax7+Ki67− and Pax7+Ki67+ cells were also examined and compared between genotypes at day 5 from isolation. Interestingly, CD82−/− cultures contained significantly more Pax7+Ki67- cells (Fig. 3f, g) and significantly less Pax7+Ki67+ cells (Fig. 3h) when compared to WT cultures (Fig. 3e), confirming delayed and/or decreased satellite cell activation. Cell cycle analyses indicated that CD82−/− cultures had less cells in the S-phase compared to WT cultures (Fig. 3i–k); however, the percentage of cells in the G0/G1 phases did not differ between the two genotypes (Fig. 3l). Furthermore, when myogenic cultures were induced to differentiate, the fusion index was significantly lower in CD82−/− cultures compared to WT controls at day 5 (p < 0.0001; Supplementary Figure 3E-N). Collectively, these studies suggest that satellite cell activation and differentiation/fusion are impaired or delayed in CD82−/− compared to WT muscles.

Fig. 3
figure 3

Satellite cell activation is transient in CD82−/− mice and Pax7 expression is retained. a, b Immunofluorescence staining of satellite cells for Pax7 (red) and MyoD (green) 72 h post-extraction from WT (a) and CD82−/− (b) animals, respectively (n = 6–10/genotype). Arrowhead in (b) points to Pax7+MyoD- cells that are more abundant in CD82−/− cultures. c Quantification of quiescent Pax7+MyoD− satellite cells at 24, 48, and 72 h following isolation and d Pax7+MyoD+ activated satellite cells from WT and CD82−/− cultures at the same timepoints (**p ≤ 0.01; ****p ≤ 0.0001). e–h Images and quantification of Pax7+Ki67− (g) and Pax7+Ki67+ (h) cells extracted from WT (e) and CD82−/− (f) cultures 5 days following isolation (*p < 0.05). Arrowheads in e and f point at Pax7+Ki67− cells, which are more abundant in CD82−/− cultures. i, j Flow cytometry cell cycle profiles of WT and CD82−/− myogenic cultures following expansion for ~ 30 days. 10,000 events were analyzed per each sample via FACS. k Quantification of percentage of cells in the S-phase and l in the G0/G1 phase from WT and CD82−/− cultures (*p ≤ 0.05; NS = not significant)

Full size image

To establish the effect of loss of CD82 expression in dystrophic muscle, CD82−/−:mdx5cv mice were generated and aged up to 1 year, with comparisons made between mdx5cv and CD82−/−:mdx5cv cohorts. CD82−/−:mdx5cv exhibited severe kyphosis compared to mdx5cv controls (Supplementary Figure 4A, B). Pulmonary function tests (plethysmography) demonstrated that CD82−/−:mdx5cv have significantly increased inspiration time compared to mdx5cv mice, confirming impaired pulmonary function (Supplementary Figure 4C) [34]. Histological H&E analyses performed on whole sections of quadriceps at 2 months (Fig. 4a, d, quantification in Supplementary Figure 4D) showed significantly decreased myofiber size in CD82−/−:mdx5cv compared to control mdx5cv and the significance increased at 1 year of age (Fig. 4b, e; quantifications in c, g), including comparisons with CD82−/− muscle (non-dystrophic). Quantification of fibrotic areas was also performed at 2 months and 1 year of age in both genotypes (Fig. 4f), which showed significantly increased fibrosis in CD82−/−:mdx5cv mice, accompanied by increased serum CK levels at this timepoint (Supplementary Figure 4E). Isometric force analyses following serial eccentric contractions demonstrated significantly heightened susceptibility to force loss, an indication of greater acute muscle injury following each eccentric contraction in CD82−/−:mdx5cv compared to control mdx5cv mice (Fig. 4h).

Fig. 4
figure 4

Ablation of CD82 in dystrophic muscle leads to worsened skeletal muscle phenotype. H&E images of the quadriceps muscles from mdx5cv (a, b) and from CD82−/−:mdx5cv mice (d, e). Images were taken from tissues at 2 months (a, d) and 1 year (b, e) of age. c Comparisons of myofiber size using ANOVA shows significantly smaller myofibers in both strains of dystrophic mice compared to CD82−/− mice, with CD82−/−:mdx5cv myofibers being the smallest. f Quantification of fibrosis at 2 months and 1 year of age shows increased presence of fibrotic tissue in young CD82−/−:mdx5cv compared to control mdx5cv mice. Examples of images used in quantification are shown in Supplementary Figure 4F, G. g Distribution plots of myofiber size show significantly smaller myofibers in CD82−/−:mdx5cv compared to control mdx5cv and CD82−/− muscles. h Isometric force analysis following serial eccentric contractions demonstrated significantly decreased muscle force production after each contraction in CD82−/−:mdx5cv compared to control mdx5cv mice. N = 6/group (**p ≤ 0.01; ***p < 0.001; ****p < 0.0001). Scale bars: 100 μm

Full size image

To determine whether a chronic demand for satellite cell activation in dystrophic muscle could explain the worsened phenotype of CD82−/−:mdx5cv, satellite cells from CD82−/−:mdx5cv and mdx5cv mice were extracted and analyzed in parallel for presence of quiescent and activated cells. Cells were again plated in slide chambers and cultured in growth medium as described for WT and CD82−/− cultures. At 24, 48, and 72 h following isolation, cells were fixed and immunostained for Pax7 with MyoD and Pax7 with Ki67 to determine the percentage of quiescent and activated satellite cells, while co-staining of MyoD with H2Aγ was used to determine the percentage of myogenic cells undergoing premature senescence/apoptosis (Fig. 5). The percentage of Pax7+MyoD- cells was significantly increased in CD82−/−:mdx5cv compared to mdx5cv cultures at 72 h (Fig. 5a, b, quantification in c), while the percentages of Pax7+MyoD+ (Fig. 5d), Pax7+Ki67+ (Fig. 5g), and MyoD+H2Aγ+ (Fig. 5h) did not differ between the genotypes at any timepoint analyzed, nor the number of non-adherent cells at each timepoint (Supplementary Figure 5D), indicating that adhesion and apoptosis were likely not increased in cultures lacking CD82. The percentage of Pax7+ satellite cells was also analyzed in tissue sections by immunofluorescence (Fig. 5i, j) in mdx5cv and CD82−/−:mdx5cv co-stained with laminin, to highlight the myofiber basal lamina. The percentage of Pax7+ cells in tissue sections did not differ between the genotypes (Fig. 5k). Myoblasts from mdx5cv and CD82−/−:mdx5cv mice were also induced to differentiate (Supplementary Figure 5A, B) and the fusion index at day 5 was significantly lower in CD82−/−:mdx5cv cultures (p < 0.05; Supplementary Figure 5C). Thus, loss of CD82 expression appears to affect/delay activation of satellite cells, with more cells likely to return to an inactive state, defined as Pax7+MyoD− by protein expression.

Fig. 5
figure 5

CD82−/−:mdx5cv satellite cells exhibit decreased activation potential compared to mdx5cv. Satellite cell-derived cultures from mdx5cv (a) and CD82−/−:mdx5cv (b) muscles stained for Pax7 (red) and MyoD (green) 72 h post isolation. Quantification plots of Pax7+MyoD− (c) and Pax7+MyoD+ (d) cells at 24, 48, and 72 h post isolation in mdx5cv and CD82−/−:mdx5cv revealed significant increase in Pax7+MyoD− cells at 72 h post isolation in CD82−/−:mdx5cv cultures (***p < 0.001). Immunofluorescence staining of primary cultures from mdx5cv (e) and CD82−/−:mdx5cv (f) mice using Pax7 (red) and Ki67 (green). Nuclei were counterstained with DAPI. g Quantification of Pax7+Ki67+ and h H2Aγ cells in mdx5cv and CD82−/−:mdx5cv cultures revealed no significant differences at 24, 48, or 72 h post extraction. i–k Immunofluorescence staining and quantification of Pax7+ satellite cells in tissue sections from mdx5cv and CD82−/−:mdx5cv mice. Pax7 staining is in red and laminin staining is in green. Satellite cells were counted in entire sections of the quadriceps but no significant difference between genotypes was observed. N = 6–10/genotype. Scale bars: 50 μm

Full size image

To study the downstream mechanism(s) responsible for decreased myofiber size and strength in dystrophic animals where CD82 expression was ablated, we examined the expression of proteins upstream and downstream of the mTOR/AKT signaling pathway, a major regulator of cell growth, protein synthesis, cellular proliferation, and cell survival in many tissues, including skeletal muscle [35]. PTEN is a known negative regulator of AKT phosphorylation and its expression levels were similar in CD82−/−:mdx5cv compared to mdx5cv muscle (Fig. 6a). The phosphorylation levels of AKT at Ser473 were also assayed by western blot, which also showed that phosphorylation at Ser473 did not differ in CD82−/−:mdx5cv muscle compared to control mdx5cv (Fig. 6a). mTOR is an important regulator of protein synthesis downstream of AKT and two known mTOR targets are 4EBP1 and S6K. We found an increase in mTOR phosphorylation at Ser 2448 in dystrophic mice lacking CD82 (Fig. 6b), while 4EBP1 and p70S6K and their respective phosphorylated forms did not differ between the genotypes (Fig. 6c).

Fig. 6
figure 6

Loss of CD82 expression in dystrophic muscle leads to increased mTOR phosphorylation at Ser 2448. Quadriceps muscle extracts from 12-week-old male mdx5cv and CD82−/−:mdx5cv mice were analyzed by Western blot and probed for multiple signaling proteins known to control cell size and quantified. a Quantification of PTEN and pAKT (Ser 473) protein levels did not show significant differences between mdx5cv and CD82−/−:mdx5cv muscle extracts. b Immunoblots for mTOR (pSer 2448) and mTOR (total) show an increase of mTOR-phosphoSer2448 in CD82−/−:mdx5cv compared to mdx5cv muscles extracts (*p = 0.02). c Analyses of p-p70S6K and p4EBP1, two known targets of mTOR signaling normalized to their total non-phosphorylated forms show no significant differences between the genotypes. N = 5/genotype

Full size image

Discussion

Tetraspanins are a heterogeneous and ubiquitous group of membrane-bound proteins that regulate a variety of physiological processes, from stem cell function to tissue regeneration and cancer progression [2, 4, 5]. Tetraspanins are known to associate with specific non-tetraspanin proteins and by doing so, they regulate membrane compartmentalization in a highly hierarchical and cell type-specific manner [3]. However, how this network of hierarchical protein interactions is established and maintained is not well understood. Several tetraspanins are expressed in skeletal muscle, such as CD81 and CD53, which have been reported to play a role in differentiation and fusion of muscle cells [36, 37]. More recently, the tetraspanin KAI/CD82 was shown to be a prospective marker for the isolation of human muscle stem cells [14] and its expression is retained by myoblasts upon differentiation into myotubes. In myogenic cells, CD82 specifically interacts with α7 integrin and the dystrophin-associated protein α-sarcoglycan [14]. Importantly, CD82 expression is reduced in cell lines and muscle tissue from Duchenne muscular dystrophy (DMD) patients, suggesting that its expression is affected by loss of dystrophin [14]. However, the function of CD82 in dystrophic muscle and whether its decreased expression is a consequence of loss of dystrophin or a compensatory mechanism in response to loss of dystrophin remains to be elucidated.

In the present study, we determined the consequences of CD82 loss-of-function in both normal and dystrophic skeletal muscle. Our data support the conclusion that CD82 is necessary for proper activation of satellite cells, as shown by both in vitro and in vivo data comparing WT and CD82−/− genotypes. Moreover, when CD82 is depleted in a dystrophic background, where muscle regeneration is continuously occurring and in demand, the disease is significantly worsened. In the absence of muscle insult, there is no significant histological change between WT and CD82−/− skeletal muscle. The importance of CD82 in muscle regeneration is demonstrated by the delayed regenerative capacity of CD82−/− muscles during acute cardiotoxin injury, as well as during chronic injury due to muscle disease, when CD82 expression was removed in the mdx5cv mouse.

Muscle repair is largely dependent on the proper function of muscle stem cells, the satellite cells [38,39,40]. In muscles lacking expression of CD82, regardless of whether our studies were performed in normal or dystrophic background, satellite cells appeared normal in number, but reluctant to divide, while retaining a seemingly quiescent, inactive state (Pax7+MyoD−). This reluctance to activate resulted in poor progression of muscle cells into a mature state, accompanied by reduced in vitro fusion capacity, which presumably lead to decreased myofiber size, poor regenerative capacity in vivo, and physiologically weakened myofibers with heightened susceptibility to injury when compared to mdx5cv controls. The severe decrease in satellite cell activation following loss of CD82 expression differs from what is reported for bone marrow stem cells, where loss of CD82 expression leads to hyperactivation and increased cell division [20, 21]. Thus, CD82 function is likely regulated through different binding partners and/or through different downstream effectors in muscle cells compared to hematopoietic stem cells (HSCs), as expected for tetraspanins.

Decreased myofiber size can arise through multiple mechanisms, including decreased myogenic cell fusion and/or decreased muscle protein synthesis. Our studies highlight possible contributions from both mechanisms following loss of CD82. Myogenic cells from CD82−/− muscle exhibit significantly decreased cell fusion in vitro, suggesting that CD82 might be directly or indirectly linked to proteins responsible for promoting fusion. Membrane-membrane fusion is one well-described function of tetraspanins, which include CD9 as a critical regulator of sperm-egg fusion [41,42,43,44]. In skeletal muscle CD9 and CD81 have been shown to negatively regulate myoblast fusion [45]. Thus, different tetraspanins might be regulating myoblast fusion and myofiber growth through antagonistic functions: CD82 and CD53 [36] being positive regulators of myoblast fusion, while CD9 and CD81 are inhibitors [45]. Collectively, these studies point to the importance of determining if expression of CD9 and CD81 is temporally preceding the expression of CD82 and CD53 during myogenic differentiation and fusion of myogenic cells, which would indicate that CD9 and CD81 are necessary to prevent myogenic cells from premature fusion. Previous studies including our own have shown that CD82 is expressed in both satellite cells and downstream myoblasts and myotubes, which leads to the fascinating hypothesis that multiple tetraspanins might be co-expressed at the same time and that regulation of myogenic fusion might occur through binding and assembly of diverse protein complexes with antagonistic function, potentially including the recently identified bona fide proteins necessary for myogenic fusion myomaker and myomerger [46].

Distinct from myoblast fusion, the present study found that dysregulation of the PTEN/AKT pathway downstream of CD82 is not responsible for the reduced myofiber size observed in CD82−/− and CD82−/−:mdx5cv dystrophic muscles. Deletion of PTEN in satellite cells has been shown to impair the ability of satellite cells to self-renew [47], which was accompanied by an increase in AKT phosphorylation at Ser473 and an increase in protein synthesis through phosphorylation of ribosomal S6 kinase, a target of mTOR/AKT [47]. Downstream of AKT, mTOR is an important regulator of protein synthesis and regulation of autophagy and decreased mTOR signaling in skeletal muscle leads to severe myopathy [48]. Interestingly, our study demonstrates an increase in mTOR phosphorylation at Ser 2448 in dystrophic mice lacking CD82, while no significant differences were seen in other known downstream targets. Increased phosphorylation of mTOR Ser2448 has been observed specifically in the skeletal muscle of lamin-A deficient mice, which are characterized by skeletal muscle dystrophy and dilated cardiomyopathy [49]. While previous studies have implicated this site as a measure of mTOR activity, recent findings also point to a possible negative feedback loop mechanism as a consequence of p70S6K activity with the ultimate effect of inhibiting rather than activating mTOR [50], indicating the complex and diverse regulation involving mTOR phosphorylation at this particular site.

Conclusions

In summary, we have identified that CD82 plays a positive function in skeletal muscle regeneration. Loss of CD82 expression in skeletal muscle causes decreased/delayed activation of satellite cells, accompanied by decreased proliferation. Loss of CD82 negatively impacts muscle regeneration, leading to a more severe manifestation of the dystrophic symptoms in CD82−/−:mdx5cv mice. Collectively, these findings suggest that upregulation of CD82 may be of therapeutic benefit in diseased muscle, including dystrophic muscle. Future studies will address the safety and potential benefits of CD82 upregulation in satellite cells or in myofibers and determine whether similar or distinct effects might be observed when CD82 upregulation is driven in different subcellular entities of skeletal muscle.

Availability of data and materials

All data presented in this article are available from the corresponding author upon reasonable request.

Abbreviations

DMD:

Duchenne muscular dystrophy

CK:

Creatine kinase

CTX:

Cardiotoxin

mTOR:

Mammalian target of rapamycin

pSer:

Phospho-Serine

AKT:

Protein kinase B

References

  1. Charrin S, Manie S, Billard M, Ashman L, Gerlier D, Boucheix C, et al. Multiple levels of interactions within the tetraspanin web. Biochem Biophys Res Commun. 2003;304(1):107–12.

    Article  CAS  PubMed  Google Scholar 

  2. Hemler ME. Tetraspanin functions and associated microdomains. Nat Rev Mol Cell Biol. 2005;6(10):801–11.

    Article  CAS  PubMed  Google Scholar 

  3. Rubinstein E. The complexity of tetraspanins. Biochem Soc Trans. 2011;39(2):501–5.

    Article  CAS  PubMed  Google Scholar 

  4. van Deventer SJ, Dunlock VE, van Spriel AB. Molecular interactions shaping the tetraspanin web. Biochem Soc Trans. 2017;45(3):741–50.

    Article  PubMed  CAS  Google Scholar 

  5. Hemler ME. Tetraspanin proteins promote multiple cancer stages. Nat Rev Cancer. 2014;14(1):49–60.

    Article  CAS  PubMed  Google Scholar 

  6. Dong JT, Lamb PW, Rinker-Schaeffer CW, Vukanovic J, Ichikawa T, Isaacs JT, et al. KAI1, a metastasis suppressor gene for prostate cancer on human chromosome 11p11.2. Science. 1995;268(5212):884–6.

    Article  CAS  PubMed  Google Scholar 

  7. Miranti CK. Controlling cell surface dynamics and signaling: how CD82/KAI1 suppresses metastasis. Cell Signal. 2009;21(2):196–211.

    Article  CAS  PubMed  Google Scholar 

  8. White A, Lamb PW, Barrett JC. Frequent downregulation of the KAI1(CD82) metastasis suppressor protein in human cancer cell lines. Oncogene. 1998;16(24):3143–9.

    Article  CAS  PubMed  Google Scholar 

  9. Custer MC, Risinger JI, Hoover S, Simpson RM, Patterson T, Barrett JC. Characterization of an antibody that can detect the Kai1/CD82 murine metastasis suppressor. Prostate. 2006;66(6):567–77.

    Article  CAS  PubMed  Google Scholar 

  10. Nagira M, Imai T, Ishikawa I, Uwabe KI, Yoshie O. Mouse homologue of C33 antigen (CD82), a member of the transmembrane 4 superfamily: complementary DNA, genomic structure, and expression. Cell Immunol. 1994;157(1):144–57.

    Article  CAS  PubMed  Google Scholar 

  11. Tsai YC, Weissman AM. Dissecting the diverse functions of the metastasis suppressor CD82/KAI1. FEBS Lett. 2011;585(20):3166–73.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  12. Engel P, Tedder TF. New CD from the B cell section of the Fifth International Workshop on Human Leukocyte Differentiation Antigens. Leuk Lymphoma. 1994;13(Suppl 1):61–4.

    Article  PubMed  Google Scholar 

  13. Bari R, Zhang YH, Zhang F, Wang NX, Stipp CS, Zheng JJ, et al. Transmembrane interactions are needed for KAI1/CD82-mediated suppression of cancer invasion and metastasis. Am J Pathol. 2009;174(2):647–60.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  14. Alexander MS, Rozkalne A, Colletta A, Spinazzola JM, Johnson S, Rahimov F, et al. CD82 is a marker for prospective isolation of human muscle satellite cells and is linked to muscular dystrophies. Cell Stem Cell. 2016;19(6):800–7.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  15. He B, Liu L, Cook GA, Grgurevich S, Jennings LK, Zhang XA. Tetraspanin CD82 attenuates cellular morphogenesis through down-regulating integrin alpha6-mediated cell adhesion. J Biol Chem. 2005;280(5):3346–54.

    Article  CAS  PubMed  Google Scholar 

  16. Sridhar SC, Miranti CK. Tetraspanin KAI1/CD82 suppresses invasion by inhibiting integrin-dependent crosstalk with c-Met receptor and Src kinases. Oncogene. 2006;25(16):2367–78.

    Article  CAS  PubMed  Google Scholar 

  17. Lee JH, Seo YW, Park SR, Kim YJ, Kim KK. Expression of a splice variant of KAI1, a tumor metastasis suppressor gene, influences tumor invasion and progression. Cancer Res. 2003;63(21):7247–55.

    CAS  PubMed  Google Scholar 

  18. Barruet E, Garcia SM, Striedinger K, Wu J, Lee S, Byrnes L, et al. Functionally heterogeneous human satellite cells identified by single cell RNA sequencing. eLife. 2020;9:e51576. https://doi.org/10.7554/eLife.51576.

  19. Camps J, Breuls N, Sifrim A, Giarratana N, Corvelyn M, Danti L, et al. Interstitial cell remodeling promotes aberrant adipogenesis in dystrophic muscles. Cell Rep. 2020;31(5):107597.

    Article  CAS  PubMed  Google Scholar 

  20. Hur J, Choi JI, Lee H, Nham P, Kim TW, Chae CW, et al. CD82/KAI1 Maintains the dormancy of long-term hematopoietic stem cells through interaction with DARC-expressing macrophages. Cell Stem Cell. 2016;18(4):508–21.

    Article  CAS  PubMed  Google Scholar 

  21. Saito-Reis CA, Marjon KD, Pascetti EM, Floren M, Gillette JM. The tetraspanin CD82 regulates bone marrow homing and engraftment of hematopoietic stem and progenitor cells. Mol Biol Cell. 2018;29(24):2946–58.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  22. Uezumi A, Nakatani M, Ikemoto-Uezumi M, Yamamoto N, Morita M, Yamaguchi A, et al. Cell-surface protein profiling identifies distinctive markers of progenitor cells in human skeletal muscle. Stem Cell Reports. 2016;7(2):263–78.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  23. Liadaki K, Casar JC, Wessen M, Luth ES, Jun S, Gussoni E, et al. beta4 integrin marks interstitial myogenic progenitor cells in adult murine skeletal muscle. J Histochem Cytochem. 2012;60(1):31–44.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  24. Luth ES, Jun SJ, Wessen MK, Liadaki K, Gussoni E, Kunkel LM. Bone marrow side population cells are enriched for progenitors capable of myogenic differentiation. J Cell Sci. 2008;121(Pt 9):1426–34.

    Article  CAS  PubMed  Google Scholar 

  25. Risinger JI, Custer M, Feigenbaum L, Simpson RM, Hoover SB, Webster JD, et al. Normal viability of Kai1/Cd82 deficient mice. Mol Carcinog. 2014;53(8):610–24.

    CAS  PubMed  Google Scholar 

  26. Banks GB, Combs AC, Chamberlain JS. Sequencing protocols to genotype mdx, mdx(4cv), and mdx(5cv) mice. Muscle Nerve. 2010;42(2):268–70.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  27. Im WB, Phelps SF, Copen EH, Adams EG, Slightom JL, Chamberlain JS. Differential expression of dystrophin isoforms in strains of mdx mice with different mutations. Hum Mol Genet. 1996;5(8):1149–53.

    Article  CAS  PubMed  Google Scholar 

  28. Wu MP, Doyle JR, Barry B, Beauvais A, Rozkalne A, Piao X, et al. G-protein coupled receptor 56 promotes myoblast fusion through serum response factor- and nuclear factor of activated T-cell-mediated signalling but is not essential for muscle development in vivo. FEBS J. 2013;280(23):6097–113.

    Article  CAS  PubMed  Google Scholar 

  29. Sohn RL, Huang P, Kawahara G, Mitchell M, Guyon J, Kalluri R, et al. A role for nephrin, a renal protein, in vertebrate skeletal muscle cell fusion. Proc Natl Acad Sci U S A. 2009;106(23):9274–9.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  30. Pasut A, Jones AE, Rudnicki MA. Isolation and culture of individual myofibers and their satellite cells from adult skeletal muscle. J Vis Exp. 2013;73:e50074.

    Google Scholar 

  31. Meng H, Janssen PM, Grange RW, Yang L, Beggs AH, Swanson LC, Cossette SA, Frase A, Childers MK, Granzier H, Gussoni E, Lawlor MW. Tissue triage and freezing for models of skeletal muscle disease. J Vis Exp. 2014;(89):51586. https://doi.org/10.3791/51586.

  32. Sacco A, Doyonnas R, Kraft P, Vitorovic S, Blau HM. Self-renewal and expansion of single transplanted muscle stem cells. Nature. 2008;456(7221):502–6.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  33. Cook PJ, Ju BG, Telese F, Wang X, Glass CK, Rosenfeld MG. Tyrosine dephosphorylation of H2AX modulates apoptosis and survival decisions. Nature. 2009;458(7238):591–6. https://doi.org/10.1038/nature07849. Epub 2009 Feb 22.

  34. Han F, Subramanian S, Price ER, Nadeau J, Strohl KP. Periodic breathing in the mouse. J Appl Physiol (1985). 2002;92(3):1133–40.

    Article  Google Scholar 

  35. Saxton RA, Sabatini DM. mTOR signaling in growth, metabolism, and disease. Cell. 2017;168(6):960–76.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  36. Liu QC, Zha XH, Faralli H, Yin H, Louis-Jeune C, Perdiguero E, et al. Comparative expression profiling identifies differential roles for Myogenin and p38alpha MAPK signaling in myogenesis. J Mol Cell Biol. 2012;4(6):386–97.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  37. Tachibana I, Hemler ME. Role of transmembrane 4 superfamily (TM4SF) proteins CD9 and CD81 in muscle cell fusion and myotube maintenance. J Cell Biol. 1999;146(4):893–904.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  38. Almada AE, Wagers AJ. Molecular circuitry of stem cell fate in skeletal muscle regeneration, ageing and disease. Nat Rev Mol Cell Biol. 2016;17(5):267–79.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  39. Dick SA, Chang NC, Dumont NA, Bell RA, Putinski C, Kawabe Y, et al. Caspase 3 cleavage of Pax7 inhibits self-renewal of satellite cells. Proc Natl Acad Sci U S A. 2015;112(38):E5246–52.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  40. Wosczyna MN, Rando TA. A muscle stem cell support group: coordinated cellular responses in muscle regeneration. Dev Cell. 2018;46(2):135–43.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  41. Chen MS, Tung KS, Coonrod SA, Takahashi Y, Bigler D, Chang A, et al. Role of the integrin-associated protein CD9 in binding between sperm ADAM 2 and the egg integrin alpha6beta1: implications for murine fertilization. Proc Natl Acad Sci U S A. 1999;96(21):11830–5.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  42. Kaji K, Oda S, Shikano T, Ohnuki T, Uematsu Y, Sakagami J, et al. The gamete fusion process is defective in eggs of Cd9-deficient mice. Nat Genet. 2000;24(3):279–82.

    Article  CAS  PubMed  Google Scholar 

  43. Le Naour F, Rubinstein E, Jasmin C, Prenant M, Boucheix C. Severely reduced female fertility in CD9-deficient mice. Science. 2000;287(5451):319–21.

    Article  PubMed  Google Scholar 

  44. Miyado K, Yamada G, Yamada S, Hasuwa H, Nakamura Y, Ryu F, et al. Requirement of CD9 on the egg plasma membrane for fertilization. Science. 2000;287(5451):321–4.

    Article  CAS  PubMed  Google Scholar 

  45. Charrin S, Latil M, Soave S, Polesskaya A, Chretien F, Boucheix C, et al. Normal muscle regeneration requires tight control of muscle cell fusion by tetraspanins CD9 and CD81. Nat Commun. 2013;4:1674.

    Article  PubMed  CAS  Google Scholar 

  46. Leikina E, Gamage DG, Prasad V, Goykhberg J, Crowe M, Diao J, et al. Myomaker and myomerger work independently to control distinct steps of membrane remodeling during myoblast fusion. Dev Cell. 2018;46(6):767–80 e7.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  47. Yue F, Bi P, Wang C, Shan T, Nie Y, Ratliff TL, et al. Pten is necessary for the quiescence and maintenance of adult muscle stem cells. Nat Commun. 2017;8:14328.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  48. Risson V, Mazelin L, Roceri M, Sanchez H, Moncollin V, Corneloup C, et al. Muscle inactivation of mTOR causes metabolic and dystrophin defects leading to severe myopathy. J Cell Biol. 2009;187(6):859–74.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  49. Ramos FJ, Chen SC, Garelick MG, Dai DF, Liao CY, Schreiber KH, et al. Rapamycin reverses elevated mTORC1 signaling in lamin A/C-deficient mice, rescues cardiac and skeletal muscle function, and extends survival. Sci Transl Med. 2012;4(144):144ra03.

    Article  CAS  Google Scholar 

  50. Figueiredo VC, Markworth JF, Cameron-Smith D. Considerations on mTOR regulation at serine 2448: implications for muscle metabolism studies. Cell Mol Life Sci. 2017;74(14):2537–45.

    Article  CAS  PubMed  Google Scholar 

Download references

Acknowledgements

The authors would like to thank the IDDRC Neurodevelopmental Behavior Core (supported by 1U54HD090255), for the plethysmography assays. The authors would like to thank Dr. Christina Hung, Dr. Mustafa Sahin, and Dr. Olivier Pourquié for helpful discussions. AP was partially supported by funds from the Office of Intramural Training and Education (OITE) at NIH. This work was supported by NIH R01AR069582 (EG) and the Muscular Dystrophy Association (USA) MDA 479606 (EG).

Funding

This work was supported by NIH R01AR069582 (EG) and the Muscular Dystrophy Association (USA) MDA 479606 (EG).

Author information

Author notes

  1. Arielle Hall and Tatiana Fontelonga contributed equally to this work.

Authors and Affiliations

  1. Division of Genetics and Genomics, Boston Children’s Hospital, Boston, MA, 02115, USA

    Arielle Hall, Tatiana Fontelonga, Alec Wright, Jeffrey Widrick & Emanuela Gussoni

  2. Division of Gastroenterology, Hepatology and Nutrition, Boston Children’s Hospital, Boston, MA, 02115, USA

    Katlynn Bugda Gwilt

  3. Laboratory of Angiogenesis and Vascular metabolism, Center for Cancer Biology, VIB and KU Leuven, 3000, Leuven, Belgium

    Alessandra Pasut

  4. F.M. Kirby Neurobiology Center, Boston Children’s Hospital, Harvard Medical School, Boston, MA, USA

    Francesco Villa

  5. Department of Cellular and Molecular Medicine, University of Arizona College of Medicine, Tucson, AZ, 85724, USA

    Cynthia K. Miranti

  6. Molecular Biology Institute, UCLA, Los Angeles, CA, 90095, USA

    Devin Gibbs

  7. The University of Pennsylvania, College of Arts and Sciences, Philadelphia, PA, 19104, USA

    Evan Jiang

  8. Department of Pathology and Laboratory Medicine and Neuroscience Research Center, Medical College of Wisconsin, Milwaukee, WI, 53226, USA

    Hui Meng & Michael W. Lawlor

  9. The Stem Cell Program at Boston Children’s Hospital, Boston, MA, 02115, USA

    Emanuela Gussoni

Authors
  1. Arielle Hall
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Tatiana Fontelonga
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Alec Wright
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Katlynn Bugda Gwilt
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Jeffrey Widrick
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Alessandra Pasut
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Francesco Villa
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Cynthia K. Miranti
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Devin Gibbs
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. Evan Jiang
    View author publications

    You can also search for this author in PubMed Google Scholar

  11. Hui Meng
    View author publications

    You can also search for this author in PubMed Google Scholar

  12. Michael W. Lawlor
    View author publications

    You can also search for this author in PubMed Google Scholar

  13. Emanuela Gussoni
    View author publications

    You can also search for this author in PubMed Google Scholar

Contributions

AH conducted the experiments, acquired and analyzed the data, and wrote the manuscript; TF conducted the experiments, acquired and analyzed the data, and wrote the manuscript; KBG conducted the experiments and acquired and analyzed the data; AW and FV acquired and analyzed the data; JW, AP, DG, EJ, HM, and MWL conducted the experiments and acquired and analyzed the data; CKM provided critical reagents; EG designed the research study, acquired and analyzed data, and wrote the manuscript. AH and TF are first co-authors and equally contributed to this work. The authors read and approved the final manuscript.

Corresponding author

Correspondence to Emanuela Gussoni.

Ethics declarations

Ethics approval and consent to participate

All experiments involving live animals were approved by the Boston Children’s Hospital animal Care and Use Committee under protocol 18-06-3730R

Consent for publication

Not applicable

Competing interests

The authors declare that they have no competing interests.

Additional information

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Supplementary Information

Additional file 1:

Supplementary Figure 1. Confirmation of CD82 knockout mice at RNA and protein levels and detection of CD82 expression in murine myoblasts and myotubes. A) Ethidium bromide gel staining showing amplification of CD82 cDNA from WT and CD82-/- mice. B) western blot analyses of 2WT and 2CD82-/- skeletal muscle tissue lysates showing expression of glycosylated and non- glycosylated CD82 protein in WT tissue, which is absent in CD82-/- extracts. A small band at ~10 Kda was seen in both WT and CD82-/- tissues, suggesting presence of an alternative CD82 product or a small cross-reactive protein. GAPDH detection was used as total protein loading control. (C, D) Immunofluorescence staining of CD82 (green) and MyoD (red) in WT mouse primary myoblasts (C) and myotubes (D). CD82 expression is detected in both myoblasts and myotubes, with increased expression in the cytoplasm of myotubes in vesicles. E) Western blot of a time-course differentiation of C2C12 myogenic cells up to 10 days, showing expression of CD82 increases during differentiation. GAPDH detection is used as total protein loading control.

Additional file 2:

Supplementary Figure 2. The number of Pax7+ satellite cells does not differ between WT and CD82-/- animals. Upper panels show single stained and merged representative immunofluorescence images of TA muscle tissue sections from non-injured (WT and CD82-/-) and cardiotoxin-injured muscles 7 days following injury (WT CTX7D and CD82-/-CTX7D) mice. Sections were immunostained for Pax7 (green) dystrophin (red) and DAPI (blue) as indicated. Arrows point to nuclei of Pax7+ cells in each panel. Quantification of the number of Pax7+ cells/myofiber from uninjured muscle and from regenerating muscle show no significant difference between the genotypes. Scale bars=50 microns. Lower panels show single myofibers isolated from EDL muscles of WT and CD82-/- mice immediately fixed and stained for Pax7 expression (red). Quantification of the number of Pax7+ cells per single myofibers between WT and CD82-/-show no significant difference (n=4/genotype).

Additional file 3:

Supplementary Figure 3. Delayed fusion in CD82-/- myoblast cultures is not due to early apoptosis/or reduced cell adhesion. (A, B) Immunofluorescence staining of cultures for MyoD (red) and H2Aγ (green) 72 hrs post-extraction from WT (A) and CD82-/- (B) animals. Arrowhead in (A) points at a MyoD+H2Aγ+ cell. (C) Quantification of H2Aγ+ cells and (D) non-adherent cells revealed no significant differences between the genotypes at all timepoints analyzed. (E) Myogenic cells from WT and (F) CD82-/- mice were plated at the same density and induced to form myotubes. At day 3 and 5 following differentiation, WT and CD82-/- cultures were immunostained for myosin heavy chain (red staining in G, H, L, M) to quantify the fusion index. The purity of the cultures assessed by MyoD staining was >80-90%. At day 3 there was no difference in myotube formation between cultures, as assessed by fusion index following staining with MF20 (I). (N) Quantification of fusion index after 5 days in differentiation media showed significantly decreased fusion in CD82-/- compared to WT cultures. Fusion index was calculated as the ratio of number of nuclei fused in MHC-myotubes over the number of total nuclei (****p<0.0001).

Additional file 4:

Supplementary Figure 4. CD82-/-:mdx5cv mice are more severely affected than mdx5cv at early age. (A) Representative image of mdx5cv and (B) CD82-/-:mdx5cv mice at 1 year of age. CD82-/-:mdx5cv mice show severe kyphosis. (C) Plethysmography assay shows significantly increased inspiration time in CD82-/-:mdx5cv compared to mdx5cv controls (***p<0.001). (D) Distribution plot of percentage of myofibers in CD82-/-:mdx5cv (red) and mdx5cv (blue) with minimum Feret diameter ranging from 10 to 90 microns. The plot shows how CD82-/-:mdx5cv mice have significantly smaller myofibers at 2 months of age. Comparisons were made with multiple t-tests (*=p≤0.05; **p≤0.01). (E) Serum creatine kinase (CK) activity assays were performed over a period of 20 weeks in independent cohorts of mice (n=4-8/timepoint/genotype). Multiple t-test analysis was made to compare the genotypes at each timepoint. The most significant changes in membrane permeability in CD82-/-:mdx5cv compared to control mdx5cv mice were observed between 5 and 10 weeks of age. (F-G) Examples of merged images of Sirius red stains used to quantify fibrotic tissue in mdx5cv and CD82-/-:mdx5cv mice at 2 months and one year. The images shown are examples of muscles at 2 months of age. Quantifications are shown in Fig. 4f.

Additional file 5:

Supplementary Figure 5. (A, B) Myogenic cells from mdx5cv and CD82-/-:mdx5cv mice were plated at the same density and induced to form myotubes. At day 5 following differentiation, cultures were immunostained for myosin heavy chain (red) to quantify the fusion index. (C) Quantification of fusion index shows significantly decreased fusion in CD82-/-:mdx5cv compared to mdx5cv cultures *p<0.05. (D) Quantification of non-adherent cells in mdx5cv and CD82-/-:mdx5cv cultures show no significant difference in their number up to 72 hrs following isolation.

Additional file 6:

Supplementary Table 1. List of primary antibodies used in this study.

Rights and permissions

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Hall, A., Fontelonga, T., Wright, A. et al. Tetraspanin CD82 is necessary for muscle stem cell activation and supports dystrophic muscle function. Skeletal Muscle 10, 34 (2020). https://doi.org/10.1186/s13395-020-00252-3

Download citation

  • Received:

  • Accepted:

  • Published:

  • DOI: https://doi.org/10.1186/s13395-020-00252-3

Keywords

Skeletal Muscle

ISSN: 2044-5040

Contact us